Our Goal
To deliver actionable results that can contribute to a clinically meaningful difference in cancer treatment.
Our Focus
The development of state-of-the-art cancer diagnostics and prognostics.
Our People
Our strength is in our people. We believe hard working, dedicated people make a significant difference.
Our Motivation
To meet and exceed expectations. Never stand still or accept second best.
From Discovery to Market
About Pacific Edge
Pacific Edge encompasses a diverse range of expertise covering all stages in the product life cycle. Our capabilities include cancer genetics, molecular oncology, bioinformatics, clinical research, technology commercialisation, marketing and sales.
Read MoreInvestor Center
Shareholder reports, key dates and services
Pacific Edge is listed on the NZX and ASX as PEB and provides an opportunity to invest into the fast growing cancer diagnostic market. Here you will find all the information you need to know about being a shareholder of Pacific Edge Limited.
Read MoreDiagnostic and Prognostic Technology
Products by Pacific Edge
Pacific Edge has its innovative bladder cancer diagnostic technology, Cxbladder in the marketplace. We are building a complete suite of Cxbladder products to meet a variety of clinical needs.
Read MoreNews & Events
Latest news updates, announcements and calendar of events.
AUA Micro-Hematuria Guideline and Medicare Timelines
Pacific Edge today notes the American Urological Association (AUA) is seeking urologist feedback on a draft standard of care guideline for the evaluation of microhematuria. The consultation is taking place under strict conditions of non-disclosure with the process commencing after 15 September 2024. [read more]
Read MoreeNews Subscription
Sign up to receive email notification of news and announcements from Pacific Edge.
Subscribe Here